

# **Veterinary Dermatology Market by Route of Administration, Product type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal type - Global Forecast to 2030**

<https://marketpublishers.com/r/VCF5E4971F26EN.html>

Date: February 2025

Pages: 385

Price: US\$ 4,950.00 (Single User License)

ID: VCF5E4971F26EN

## **Abstracts**

The global veterinary dermatology market is projected to reach USD 30.31 billion by 2030 from USD 20.11 billion in 2025, at a CAGR of 8.5% during the forecast period. The Veterinary Dermatology Market is experiencing significant growth, driven by the expanding companion animal population and increasing pet ownership. Growing concerns about infectious zoonotic diseases have further influenced the demand for dermatological treatments. Government and animal welfare organizations are actively promoting awareness initiatives, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. Moreover, the rising adoption of pet insurance and high animal healthcare expenditure are supporting market growth by improving access to specialized dermatological care. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Additionally, increasing resistance to parasiticides poses a significant concern, reducing the effectiveness of common dermatological treatments. Despite these restraints, advancements in veterinary dermatology, including novel therapeutics and diagnostic techniques, continue to drive market opportunities.

'The Oral segment is projected to grow at the highest CAGR during the forecast period of 2025-2030.'

The oral segment is projected to grow at the highest CAGR during 2025-2030 due to its

ease of administration and improved pet owner compliance. Oral medications, including tablets, capsules, and chewable formulations, offer a convenient alternative to topical and injectable treatments. Increasing veterinary recommendations for systemic treatments over topical solutions and the development of palatable formulations are boosting demand. Additionally, advancements in drug delivery systems, such as sustained-release oral formulations, contribute to the segment's growth in the veterinary dermatology market.

'Antiparasitic Drugs segment accounted the largest market in 2024 in veterinary dermatology market.'

The antiparasitic drugs segment accounted for the largest market share in 2024 due to the rising prevalence of parasitic infections in animals. These drugs, including flea and tick preventives, are widely used for both treatment and prevention. Increasing pet adoption and awareness about zoonotic diseases are fueling the demand for antiparasitic treatments. Moreover, the growing availability of combination therapies that target multiple parasites has driven market expansion. Key industry players are launching innovative formulations with improved efficacy and longer protection durations, further strengthening the segment's dominance.

'Parasitic infection is expected to witness the fastest growth rate in the global veterinary dermatology market.'

Parasitic infections are expected to witness the fastest growth rate in the veterinary dermatology market. The high incidence of flea, tick, and mite infestations in pets, especially in warm and humid regions, is driving demand for effective treatments. Parasitic dermatitis can cause severe itching, hair loss, and secondary bacterial infections, increasing the need for veterinary care. Advancements in diagnostic methods and increasing availability of prescription and over-the-counter treatments contribute to the segment's rapid growth. Moreover, heightened pet owner awareness of parasite prevention further supports market expansion.

'Companion animals segment has accounted the largest market share in the veterinary dermatology market.'

The companion animals segment accounted for the largest market share in 2024, driven by increasing pet ownership and growing expenditure on animal healthcare. Dogs and cats are highly susceptible to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, necessitating frequent dermatological treatments. The rising

trend of pet humanization and demand for premium veterinary care further boost market growth. Additionally, advancements in dermatological therapeutics, including biologics and targeted therapies, enhance treatment outcomes for companion animals, reinforcing the segment's dominance in the market.

“Veterinary Hospitals and Clinics segment is expected to witness the highest growth rate in the global veterinary dermatology market.”

Veterinary hospitals and clinics are expected to witness the highest growth rate, driven by the increasing number of veterinary visits and the availability of specialized dermatology services. These facilities provide comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical interventions for severe skin conditions. The rise in dermatology-focused veterinary clinics and expansion of telemedicine services for dermatological consultations contribute to segment growth. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, further increasing demand in this segment.

“North America has accounted for the largest market share in 2024.”

North America accounted for the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative dermatological treatments. Rising awareness about pet skin health, coupled with increasing spending on veterinary care, drives market expansion. Additionally, the growing demand for premium pet dermatology products, including hypoallergenic shampoos, medicated sprays, and prescription drugs, contributes to North America's market dominance in the global veterinary dermatology industry.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 45%, Tier 2 – 20%, and Tier 3 – 35% • By Designation: C-level – 35%, Director-level – 25%, and Others – 40% • By Region: North America - 40%, Europe – 25%, APAC – 20%, Latin America – 10%, Middle East & Africa – 5%

Breakdown of demand-side primary interviews: • By Company Type: Veterinary Hospitals and Clinics – 55%, Animal Shelters and Clinics – 30%, and Other End Users – 15% • By Designation: Veterinary Professionals – 35%, Pet Owners – 30%, Livestock Farmers – 25% and Government Officers – 10% • By Region: North America - 40%, Europe – 25%, APAC – 20%, Latin America – 10%, Middle East & Africa – 5%

## Research Coverage

This report studies veterinary dermatology market based on route of administration, product types, condition types, animal types, end users, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

## Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

Analysis of key drivers (Expanding companion animal population and pet ownership, Growing concerns about infectious zoonotic diseases, Rising Awareness initiatives by government and animal welfare organizations, Increasing adoption of pet insurance and high animal healthcare expenditure), restraints (Rising pet care costs, Restrictions on use of parasiticides for food-producing animals), opportunities (Technological advancements and product launches, High growth potential in emerging economies, Surging number of veterinary practitioners in developed markets), and challenges (Growing resistance to parasiticides, Diversity in parasite species) influencing the growth of veterinary dermatology market.

**Product Development/Innovation:** Detailed insights on upcoming technologies, research and development activities, and product launches in veterinary dermatology market.

**Market Development:** Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of veterinary dermatology treatments across regions.

**Market Diversification:** Exhaustive information about products, untapped regions, recent developments, and investments in veterinary dermatology market.

**Competitive Assessment:** In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in veterinary dermatology market.

## Contents

### 1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
  - 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 STUDY SCOPE
  - 1.3.1 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS

### 2 RESEARCH METHODOLOGY

- 2.1 RESEARCH APPROACH
  - 2.1.1 SECONDARY DATA
    - 2.1.1.1 Key data from secondary sources
  - 2.1.2 PRIMARY DATA
    - 2.1.2.1 Key data from primary sources
    - 2.1.2.2 Key industry insights
- 2.2 MARKET SIZE ESTIMATION
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.4 MARKET SHARE ESTIMATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RISK ASSESSMENT
- 2.7 RESEARCH LIMITATIONS
  - 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  - 2.7.2 SCOPE-RELATED LIMITATIONS

### 3 EXECUTIVE SUMMARY

### 4 PREMIUM INSIGHTS

- 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY DERMATOLOGY MARKET
- 4.2 NORTH AMERICA: VETERINARY DERMATOLOGY MARKET OVERVIEW
- 4.3 VETERINARY DERMATOLOGY MARKET: REGIONAL MIX
- 4.4 VETERINARY DERMATOLOGY MARKET, BY COUNTRY
- 4.5 VETERINARY DERMATOLOGY MARKET: EMERGING VS. DEVELOPED

## MARKETS

### 5 MARKET OVERVIEW

#### 5.1 INTRODUCTION

#### 5.2 MARKET DYNAMICS

##### 5.2.1 DRIVERS

5.2.1.1 Expanding companion animal population and pet ownership

5.2.1.2 Growing concerns about infectious zoonotic diseases

5.2.1.3 Rising awareness initiatives by government and animal welfare organizations

5.2.1.4 Increasing adoption of pet insurance and high animal healthcare expenditure

##### 5.2.2 RESTRAINTS

5.2.2.1 Rising pet care costs

5.2.2.2 Restrictions on use of parasiticides for food-producing animals

##### 5.2.3 OPPORTUNITIES

5.2.3.1 Technological advancements and product launches

5.2.3.2 High growth potential in emerging economies

5.2.3.3 Surging number of veterinary practitioners in developed markets

##### 5.2.4 CHALLENGES

5.2.4.1 Growing resistance to parasiticides

5.2.4.2 Diversity in parasite species

#### 5.3 INDUSTRY TRENDS

5.3.1 RISE IN PET OWNERSHIP, HUMANIZATION OF PETS, AND INCREASED FOCUS ON PET WELLNESS PROGRAMS

5.3.2 RISING USE OF DIAGNOSTICS AND WEARABLE TECHNOLOGY FOR EARLY DETECTION

#### 5.4 TECHNOLOGY ANALYSIS

##### 5.4.1 KEY TECHNOLOGIES

5.4.1.1 Topical nanomedicine

5.4.1.2 Biologic therapies

##### 5.4.2 COMPLEMENTARY TECHNOLOGIES

5.4.2.1 Phototherapy

5.4.2.2 Hydrotherapy

##### 5.4.3 ADJACENT TECHNOLOGIES

5.4.3.1 Telemedicine platforms

5.4.3.2 Wearable devices

#### 5.5 PORTER'S FIVE FORCES ANALYSIS

##### 5.5.1 COMPETITIVE RIVALRY

5.5.1.1 Established players

- 5.5.1.2 Continuous innovation
- 5.5.2 BARGAINING POWER OF BUYERS
  - 5.5.2.1 Consolidated veterinary groups
  - 5.5.2.2 Demand for affordable solutions
- 5.5.3 BARGAINING POWER OF SUPPLIERS
  - 5.5.3.1 Specialized raw materials
  - 5.5.3.2 Quality compliance
- 5.5.4 THREAT OF SUBSTITUTES
  - 5.5.4.1 Limited alternatives
  - 5.5.4.2 Specialized treatments
- 5.5.5 THREAT OF NEW ENTRANTS
  - 5.5.5.1 High R&D costs
  - 5.5.5.2 Regulatory requirements
- 5.6 REGULATORY LANDSCAPE
  - 5.6.1 REGULATORY ANALYSIS
  - 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.7 PATENT ANALYSIS
  - 5.7.1 PATENT PUBLICATION TRENDS FOR VETERINARY DERMATOLOGY MARKET
  - 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.8 TRADE ANALYSIS
  - 5.8.1 IMPORT AND EXPORT SCENARIO FOR VETERINARY DERMATOLOGY PRODUCTS
- 5.9 PRICING ANALYSIS
  - 5.9.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT TYPE
  - 5.9.2 AVERAGE SELLING PRICE TREND OF VETERINARY DERMATOLOGY PRODUCT TYPES, BY REGION
- 5.10 REIMBURSEMENT ANALYSIS
- 5.11 KEY CONFERENCES AND EVENTS
- 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  - 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  - 5.12.2 BUYING CRITERIA
- 5.13 UNMET NEEDS/END USER EXPECTATIONS IN VETERINARY DERMATOLOGY MARKET
- 5.14 IMPACT OF GENERATIVE AI ON VETERINARY DERMATOLOGY MARKET
- 5.15 ECOSYSTEM ANALYSIS
- 5.16 CASE STUDY ANALYSIS
  - 5.16.1 ZOETIS LAUNCHED APOQUEL TABLET FOR ALLERGIC DERMATITIS

5.16.2 ELANCO LAUNCHED ZENRELIA TABLET FOR CANINE ATOPIC DERMATITIS

5.16.3 VIRBAC LAUNCHED ALLERDERM SPOT-ON TOPICAL PRODUCT FOR SKIN BARRIER REPAIR

5.17 SUPPLY CHAIN ANALYSIS

5.18 VALUE CHAIN ANALYSIS

5.19 ADJACENT MARKETS FOR VETERINARY DERMATOLOGY MARKET

5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.21 INVESTMENT AND FUNDING SCENARIO

## **6 VETERINARY DERMATOLOGY MARKET, BY ROUTE OF ADMINISTRATION**

6.1 INTRODUCTION

6.2 TOPICAL

6.2.1 HIGH PREVALENCE OF ECTOPARASITIC INFESTATIONS AMONG PETS TO DRIVE DEMAND

6.3 INJECTABLES

6.3.1 RAPID ABSORPTION AND HIGH BIOAVAILABILITY TO FUEL GROWTH OF INJECTABLE PRODUCTS

6.4 ORAL

6.4.1 COMPREHENSIVE APPROACH TO MANAGING CHRONIC AND SEVERE DERMATOLOGICAL DISORDERS

## **7 VETERINARY DERMATOLOGY MARKET, BY PRODUCT TYPE**

7.1 INTRODUCTION

7.2 ANTIPARASITIC DRUGS

7.2.1 HIGH PREVALENCE OF PARASITIC INFECTIONS IN ANIMALS TO DRIVE DEMAND

7.3 ANTIFUNGAL DRUGS

7.3.1 INCREASING INSTANCES OF YEAST DERMATITIS AND CANDIDIASIS TO DRIVE DEMAND

7.4 ANTIBACTERIAL DRUGS

7.4.1 GROWTH HINDERED BY RISING CONCERNS OVER ANTIMICROBIAL RESISTANCE

7.5 MONOCLONAL ANTIBODIES

7.5.1 RISING INVESTMENT IN R&D TO BOOST SEGMENTAL GROWTH

7.6 OTHER PRODUCT TYPES

## **8 VETERINARY DERMATOLOGY MARKET, BY CONDITION TYPE**

### 8.1 INTRODUCTION

### 8.2 PARASITIC INFECTIONS

8.2.1 HIGH OCCURRENCE IN BOTH COMPANION AND LIVESTOCK ANIMALS TO DRIVE DEMAND FOR PREVENTIVE MEASURES

### 8.3 INFECTIOUS DISEASES

8.3.1 HIGH PREVALENCE OF FUNGAL INFECTIONS TO DRIVE GROWTH

### 8.4 AUTOIMMUNE SKIN DISEASES

8.4.1 LOWER OCCURRENCE OF THESE DISEASES CONTRIBUTE TO SMALLER MARKET SHARE

### 8.5 SKIN CANCER

8.5.1 GROWING AWARENESS ABOUT IMPORTANCE OF EARLY DETECTION AND TREATMENT OF SKIN CANCER TO DRIVE GROWTH

### 8.6 OTHER CONDITION TYPES

## **9 VETERINARY DERMATOLOGY MARKET, BY ANIMAL TYPE**

### 9.1 INTRODUCTION

### 9.2 COMPANION ANIMALS

#### 9.2.1 DOGS

9.2.1.1 Growing dog population and high pet ownership to drive growth

#### 9.2.2 CATS

9.2.2.1 Growing awareness of feline health to drive growth

#### 9.2.3 HORSES

9.2.3.1 Initiatives related to adoption to drive growth

#### 9.2.4 OTHER COMPANION ANIMALS

### 9.3 LIVESTOCK ANIMALS

#### 9.3.1 CATTLE

9.3.1.1 Economic importance of dairy and beef cattle to drive growth

#### 9.3.2 SWINE

9.3.2.1 Rising global swine population and pork consumption to drive growth

#### 9.3.3 POULTRY

9.3.3.1 Increasing demand for milk and dairy products to drive growth

#### 9.3.4 OTHER LIVESTOCK ANIMALS

## **10 VETERINARY DERMATOLOGY MARKET, BY END USER**

### 10.1 INTRODUCTION

## 10.2 VETERINARY HOSPITALS AND CLINICS

10.2.1 GROWING DEMAND FOR SPECIALIZED SKINCARE AND TREATMENTS TO DRIVE MARKET

## 10.3 ANIMAL SHELTERS AND RESCUES

10.3.1 NGO AND ANIMAL WELFARE ORGANIZATIONS TO KEEP SUPPORTING DERMATOLOGICAL TREATMENT IN VETERINARY MARKET

## 10.4 OTHER END USERS

# 11 VETERINARY DERMATOLOGY MARKET, BY REGION

## 11.1 INTRODUCTION

### 11.2 NORTH AMERICA

#### 11.2.1 MACROECONOMIC OUTLOOK

#### 11.2.2 US

11.2.2.1 High pet ownership rates to drive growth

#### 11.2.3 CANADA

11.2.3.1 Rising concerns about pet skin health to drive market

### 11.3 EUROPE

#### 11.3.1 MACROECONOMIC OUTLOOK

#### 11.3.2 GERMANY

11.3.2.1 Rising poultry consumption and dairy industry to drive market

#### 11.3.3 UK

11.3.3.1 Large pet ownership and zoonotic disease prevention to drive market

#### 11.3.4 FRANCE

11.3.4.1 Stable animal healthcare spending to support market growth

#### 11.3.5 ITALY

11.3.5.1 Expanding livestock industry to drive market

#### 11.3.6 SWITZERLAND

11.3.6.1 High standards in animal health to drive growth

#### 11.3.7 SPAIN

11.3.7.1 Growing pet population and strong dairy industry to drive market

#### 11.3.8 REST OF EUROPE

### 11.4 ASIA PACIFIC

#### 11.4.1 MACROECONOMIC OUTLOOK

#### 11.4.2 JAPAN

11.4.2.1 Rising demand for animal products and increasing pet ownership to drive growth

#### 11.4.3 CHINA

11.4.3.1 Expanding urban pet market and high meat consumption to fuel market

#### 11.4.4 INDIA

11.4.4.1 Growing pet adoption and veterinary shortage to drive market

#### 11.4.5 AUSTRALIA

11.4.5.1 Growing pet ownership and rising spending on veterinary care to drive market

#### 11.4.6 NEW ZEALAND

11.4.6.1 Increased pet ownership and demand for advanced dermatology treatments to drive market

#### 11.4.7 SOUTH KOREA

11.4.7.1 Increasing awareness and adoption of preventive healthcare measures to drive market

#### 11.4.8 REST OF ASIA PACIFIC

### 11.5 LATIN AMERICA

#### 11.5.1 MACROECONOMIC OUTLOOK

#### 11.5.2 BRAZIL

11.5.2.1 Strong veterinary infrastructure and expanding livestock industry to drive market

#### 11.5.3 MEXICO

11.5.3.1 Expanding livestock and poultry sectors to drive market

#### 11.5.4 REST OF LATIN AMERICA

### 11.6 MIDDLE EAST & AFRICA

#### 11.6.1 MACROECONOMIC OUTLOOK

#### 11.6.2 GCC COUNTRIES

##### 11.6.2.1 Kingdom of Saudi Arabia (KSA)

11.6.2.1.1 Vision 2030 investments to drive market

##### 11.6.2.2 United Arab Emirates (UAE)

11.6.2.2.1 Significant livestock population to fuel demand

##### 11.6.2.3 Rest of GCC Countries

#### 11.6.3 REST OF MIDDLE EAST & AFRICA

## 12 COMPETITIVE LANDSCAPE

### 12.1 OVERVIEW

### 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN

### 12.3 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET (2020–2024)

### 12.4 MARKET SHARE ANALYSIS, 2024

12.4.1 RANKING OF KEY MARKET PLAYERS, 2024

### 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 12.5.5.1 Company footprint
  - 12.5.5.2 Region footprint
  - 12.5.5.3 Route of administration footprint
  - 12.5.5.4 Product type footprint
  - 12.5.5.5 Condition type footprint
  - 12.5.5.6 Animal type footprint
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 12.6.1 PROGRESSIVE COMPANIES
  - 12.6.2 RESPONSIVE COMPANIES
  - 12.6.3 DYNAMIC COMPANIES
  - 12.6.4 STARTING BLOCKS
  - 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 12.7 BRAND/PRODUCT COMPARISON
- 12.8 R&D EXPENDITURE OF KEY PLAYERS
- 12.9 COMPANY VALUATION AND FINANCIAL METRICS
  - 12.9.1 COMPANY VALUATION
  - 12.9.2 FINANCIAL METRICS
- 12.10 COMPETITIVE SCENARIO
  - 12.10.1 PRODUCT APPROVALS/LAUNCHES
  - 12.10.2 DEALS
  - 12.10.3 EXPANSIONS
  - 12.10.4 OTHER DEVELOPMENTS

## **13 COMPANY PROFILES**

- 13.1 KEY PLAYERS
  - 13.1.1 ELANCO ANIMAL HEALTH INCORPORATED
    - 13.1.1.1 Business overview
    - 13.1.1.2 Products offered
    - 13.1.1.3 Recent developments
      - 13.1.1.3.1 Product launches and approvals
      - 13.1.1.3.2 Deals
      - 13.1.1.3.3 Expansions
    - 13.1.1.4 MnM view

- 13.1.1.4.1 Right to win
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 MERCK & CO., INC
  - 13.1.2.1 Business overview
  - 13.1.2.2 Products offered
  - 13.1.2.3 Recent developments
    - 13.1.2.3.1 Product launches and approvals
    - 13.1.2.3.2 Deals
    - 13.1.2.3.3 Expansions
    - 13.1.2.3.4 Other developments
  - 13.1.2.4 MnM view
    - 13.1.2.4.1 Right to win
    - 13.1.2.4.2 Strategic choices
    - 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 VIRBAC
  - 13.1.3.1 Business overview
  - 13.1.3.2 Products offered
  - 13.1.3.3 Recent developments
    - 13.1.3.3.1 Deals
    - 13.1.3.3.2 Expansions
    - 13.1.3.3.3 Other developments
  - 13.1.3.4 MnM view
    - 13.1.3.4.1 Right to win
    - 13.1.3.4.2 Strategic choices
    - 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 ZOETIS INC.
  - 13.1.4.1 Business overview
  - 13.1.4.2 Products offered
  - 13.1.4.3 Recent developments
    - 13.1.4.3.1 Product launches and approvals
    - 13.1.4.3.2 Deals
    - 13.1.4.3.3 Expansions
    - 13.1.4.3.4 Other developments
  - 13.1.4.4 MnM view
    - 13.1.4.4.1 Right to win
    - 13.1.4.4.2 Strategic choices
    - 13.1.4.4.3 Weaknesses and competitive threats
- 13.1.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

- 13.1.5.1 Business overview
- 13.1.5.2 Products offered
- 13.1.5.3 Recent developments
  - 13.1.5.3.1 Product approvals
  - 13.1.5.3.2 Deals
- 13.1.5.4 MnM view
  - 13.1.5.4.1 Right to win
  - 13.1.5.4.2 Strategic choices
  - 13.1.5.4.3 Weaknesses and competitive threats
- 13.1.6 VETOQUINOL
  - 13.1.6.1 Business overview
  - 13.1.6.2 Products offered
  - 13.1.6.3 Recent developments
    - 13.1.6.3.1 Product approvals
- 13.1.7 DECHRA PHARMACEUTICALS PLC
  - 13.1.7.1 Business overview
  - 13.1.7.2 Products offered
  - 13.1.7.3 Recent developments
    - 13.1.7.3.1 Product approvals
    - 13.1.7.3.2 Deals
- 13.1.8 HESTER BIOSCIENCES LIMITED
  - 13.1.8.1 Business overview
  - 13.1.8.2 Products offered
- 13.1.9 PETIQ, INC.
  - 13.1.9.1 Business overview
  - 13.1.9.2 Products offered
  - 13.1.9.3 Recent developments
    - 13.1.9.3.1 Other developments
- 13.1.10 OUROFINO SAUDE ANIMAL
  - 13.1.10.1 Business overview
  - 13.1.10.2 Products offered
- 13.1.11 SWEDENCARE
  - 13.1.11.1 Business overview
  - 13.1.11.2 Products offered
  - 13.1.11.3 Recent developments
    - 13.1.11.3.1 Deals
- 13.1.12 ORION CORPORATION
  - 13.1.12.1 Business overview
  - 13.1.12.2 Products offered

**13.1.13 NORBROOK**

- 13.1.13.1 Business overview
- 13.1.13.2 Products offered
- 13.1.13.3 Recent developments
  - 13.1.13.3.1 Product launches
  - 13.1.13.3.2 Expansions

**13.1.14 CEVA SANTE ANIMALE**

- 13.1.14.1 Business overview
- 13.1.14.2 Products offered
- 13.1.14.3 Recent developments
  - 13.1.14.3.1 Deals

**13.1.15 BIMEDA, INC.**

- 13.1.15.1 Business overview
- 13.1.15.2 Products offered
- 13.1.15.3 Recent developments
  - 13.1.15.3.1 Product launches
  - 13.1.15.3.2 Deals

**13.2 OTHER PLAYERS**

- 13.2.1 INDIAN IMMUNOLOGICALS LTD.
- 13.2.2 VETANCO
- 13.2.3 CHANELLE PHARMA
- 13.2.4 PEGASUS LABORATORIES, INC.
- 13.2.5 KYORITSU SEIYAKU CORPORATION
- 13.2.6 AVET HEALTH
- 13.2.7 ANIMALDERMA SRLS
- 13.2.8 LETI PHARMA
- 13.2.9 HUVEPHARMA, INC.
- 13.2.10 VETPLUS

**14 APPENDIX****14.1 DISCUSSION GUIDE****14.2 KNOWLEDGESTORE: MARKETSDANDMARKETS' SUBSCRIPTION PORTAL****14.3 CUSTOMIZATION OPTIONS****14.4 RELATED REPORTS****14.5 AUTHOR DETAILS**

## I would like to order

Product name: Veterinary Dermatology Market by Route of Administration, Product type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal type - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/VCF5E4971F26EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VCF5E4971F26EN.html>